The DEBIT trial: An intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - A cluster randomized controlled trial

Psychological Medicine

Volumn 38, Issue 5, 2008, Pages 705-715

  Thompson, A ^a   Sullivan, S A ^a   Barley, M ^a   Strange, S O ^a   Moore, L ^b   Rogers, P ^c   Sipos, A ^a   Harrison, G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLAMORGAN   (United Kingdom)

Author keywords

Antipsychotics; Evidence based guidelines; Polypharmacy; Randomized controlled trial

Indexed keywords

ADULT; ARTICLE; COGNITIVE THERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; EDUCATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSE; PHYSICIAN; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIC DEPARTMENT; REMINDER SYSTEM; RISK ASSESSMENT;

ADULT; ANTIPSYCHOTIC AGENTS; CLUSTER ANALYSIS; COMMITMENT OF MENTALLY ILL; CURRICULUM; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; ENGLAND; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; INSERVICE TRAINING; MALE; MIDDLE AGED; PATIENT CARE TEAM; PRISONERS; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTIC DISORDERS;

EID: 41649084387     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329170700147X     Document Type: Article

References (34)

1. APA (2004). Practice Guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association: Washington, DC.
2. Avorn J, Soumerai SB, Everitt DE, Ross-Degnan D, Beers MH, Sherman D, Salem-Schatz SR, Fields D (1992). A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. New England Journal of Medicine 327, 168-173.
3. Barley M, Pope C, Chilvers R, Sipos A, Harrison G (in press). Psychiatrists' attitudes to clinical practice guidelines for the pharmacological treatment of schizophrenia: a qualitative study. Journal of Mental Health.
4. Berings D, Blondeel L, Habraken H (1994). The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. European Journal of Clinical Pharmacology 46, 501-505.
5. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA (1998). Getting research findings into practice: closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. British Medical Journal 317, 465-468.
6. Canadian Psychiatric Association (1998). Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia. Canadian Journal of Psychiatry 43 (Suppl. 2), S25-S40.
7. Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, Salvatore P, Egli S, Baldessarini RJ (2002). Inpatient antipsychotic drug use in 1998, 1993 and 1989. American Journal of Psychiatry 159, 1932-1935.
8. Chilvers R, Harrison G, Sipos A, Barley M (2002). Evidence into practice: application of psychological models of change in evidence-based implementation. British Journal of Psychiatry 181, 99-101.
9. Donner A, Klar N (2000). Analysis of binary outcomes. In Design and Analysis of Cluster Randomised Trials in Health Research, pp. 79-110. Arnold: London.
10. Ereshefsky L (1999). Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Journal of Clinical Psychiatry 60 (Suppl. 10), 20-30.
11. Forensic Psychology Practice Ltd (1999). Working with Sex Offenders. Forensic Psychology Practice Ltd: London.
12. Freemantle N, Nazareth I, Eccles M, Wood J, Haines A (2002). A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice. British Journal of General Practice 52, 290-295.
13. Freudenreich O, Goff DC (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica 106, 323-330.
14. Gill PS, Makela M, Vermeulen KM, Freemantle N, Ryan G, Bond C, Thorsen T, Haaifer-Ruskamp FM (1999). Changing doctor prescribing behaviour. Pharmacy World and Science 21, 158-167.
15. Grimshaw JM, Eccles MP, Walker AE, Thomas RE (2002). Changing physicians' behavior: what works and thoughts on getting more things to work. Journal of Continuing Education in the Health Professions 22, 237-243.
16. Harrington M, Lelliott P, Paton C, Okacha C, Duffett R, Sensky T (2002). The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin 26, 414-418.
17. Hogman G, Sandamas G (2000). A Question of Choice. NSF: London.
18. Ito H, Koyama A, Higuchi T (2005). Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British Journal of Psychiatry 187, 243-247.
19. Joint Formulary Committee (2003). British National Formulary, 46th edn. British Medical Association and Royal Pharmaceutical Society of Great Britain: London.
20. Joint Formulary Committee (2004). British National Formulary, 47th edn. British Medical Association and Royal Pharmaceutical Society of Great Britain: London.
21. McGorry P, Killackey E, Elkins K, Lambert M, Lambert T (2003). Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australian Psychiatry 11, 136-158.
22. MRC (2000). A Framework for Development and Evaluation of RCTs for Complex Interventions to Improve Health. Medical Research Council: London.
23. NICE (2002). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology appraisal Guidance No. 43. National Institute for Clinical Excellence: London.
24. Oxman AD, Thomson MA, Davis DA, Haynes RB (1995). No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Canadian Medical Association Journal 153, 1423-1431.
25. Prochaska JO, DiClemente CC (1986). Towards a Comprehensive Model of Change. In Treating Addictive Behaviours: Processes of Change (ed. W. R. Miller and N. Heather), pp. 3-27. Plenum Press: New York.
26. Rawson RA (1999). Treatment for Stimulant Use Disorders: Treatment Improvement Protocol (TIP) Series 33. Rockville, MD: U.S. Department of Health and Human Services.
27. Ray WA, Blazer DG, Schaffner W, Federspiel CF (1987). Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. American Journal of Public Health 77, 1448-1450.
28. Sipos A (2004). Preparing the way for evidence based implementation: A pharmacoepidemiological study of antipsychotic prescribing practice informing the design of a cluster randomised trial (Thesis). University of Bristol.
29. Soumerai SB, Avorn J (1990). Principles of educational outreach ('academic detailing') to improve clinical decision making. Journal of the American Medical Association 263, 549-556.
30. Stahl SM (2002). Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatrica Scandinavica 106, 321-322.
31. Taylor D, Mace S, Mir S, Kerwin R (2000). A prescription survey of the use of atypical antipsychiotics for hospital inpatients in the United Kingdom. International Journal of Psychiatry in Clinical Practice 4, 41-46.
32. Thomson O'Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL (1997). Educational outreach visits: effects on professional practice and health care outcomes. The Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD000409. doi:10.1002/14651858.
33. Van Eijk EC, Avorn J, Porsius AJ, de Boer A (2001). Reducing prescribing of highly anticholingeric antidepressants for elderly people: randomised trial of group versus individual academic detailing. British Medical Journal 322, 654-657.
34. Wensing M, Van Der Weijden T, Grol R (1998). Implementing guidelines and innovations in general practice: which interventions are effective? British Journal of General Practice 48, 991-997.